@article {Racine-Brzostek2021.08.04.21261561, author = {Sabrina E. Racine-Brzostek and Jim Yee and Ashley Sukhu and Yuqing Qiu and Sophie Rand and Paul Barone and Ying Hao and He S. Yang and Qing H Meng and Fred S Apple and Yuanyuan Shi and Amy Chadburn and Encouse Golden and Silvia C. Formenti and Melissa M. Cushing and Zhen Zhao}, title = {More rapid, robust and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals}, elocation-id = {2021.08.04.21261561}, year = {2021}, doi = {10.1101/2021.08.04.21261561}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Longitudinal studies are needed to evaluate the SARS-CoV-2 mRNA vaccine antibody response under {\textquotedblleft}real-world{\textquotedblright} conditions. This longitudinal study investigated the quantity and quality of SARS-CoV-2 antibody response in 846 specimens from 350 subjects: comparing BNT162b2-vaccinated individuals (19 previously diagnosed with COVID-19 [RecoVax]; 49 never been diagnosed [Na{\"\i}veVax]) to 122 hospitalized unvaccinated (HospNoVax) and 160 outpatient unvaccinated (OutPtNoVax) COVID-19 patients.Na{\"\i}veVax experienced a delay in generating SARS-CoV-2 total antibody levels (TAb) and neutralizing antibodies (SNAb) after the 1st vaccine dose (D1), but a rapid increase in antibody levels was observed after the 2nd dose (D2). However, these never reached the robust levels observed in RecoVax. In fact, Na{\"\i}veVax TAb and SNAb levels decreased 4-weeks post-D2 (p=0.003;p\<0.001). For the most part, RecoVax TAb persisted throughout this study, after reaching maximal levels 2-weeks post-D2; but SNAb decreased significantly \~{}6-months post-D1 (p=0.002). Although Na{\"\i}veVax avidity lagged behind that of RecoVax for most of the follow-up periods, Na{\"\i}veVax did reach similar avidity by \~{}6-months post-D1. These data suggest that one vaccine dose elicits maximal antibody response in RecoVax and may be sufficient. Also, despite decreasing levels in TAb and SNAb overtime, long-term avidity maybe a measure worth evaluating and possibly correlating to vaccine efficacy.Competing Interest StatementZZ has received seed instruments from ET Healthcare and sponsored research funding from ET Healthcare and Roche Diagnostics. SRB has received sponsored research funding from Roche Diagnostics. The remaining authors have declared that no conflict of interest exist.Funding StatementZZ has received seed instruments from ET Healthcare and sponsored research funding from ET Healthcare and Roche Diagnostics. SRB has received sponsored research funding from Roche Diagnostics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The retrospective (IRB$\#$2003021671) and prospective (IRB$\#$2011022929; IRB$\#$2004021831) studies in this manuscript were performed at NewYorkPresbyterian Hospital/Weill Cornell Medical Center (NYP/WCMC) with approval by the Institutional Review Board of Weill Cornell Medicine (WCM).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAny data inquires may be made to the corresponding authors and will be reviewed according the to NYP/Weill Cornell institutional guidelines.COVID-19Coronavirus Disease-2019D11st dose vaccineD22nd dose vaccineDAOSdays after onset of symptomsdRrelative dissociation rateEDEmergency DepartmentEUAemergency use authorizationFDAU.S. Food and Drug AdministrationHospNoVaxhospitalized acutely infected non-vaccinated cohortNa{\"\i}veVaxnaive vaccinated cohortNnucleocapsidNYPNew York PresbyterianOutPtNoVaxconvalescent non-vaccinated COVID-19 outpatientsPIdays post-infection (SARS-CoV-2)PRNTplaque reduction neutralization testPsVpseudovirus neutralization testRBDreceptor-binding domainRecoVaxrecovered vaccinated cohortRFUrelative fluorescence unitRT-PCRreal-time reverse transcription polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 2SDstandard deviationSNABsurrogate neutralizing antibodyTAbtotal antibodyWCMCWeill Cornell Medical Center.}, URL = {https://www.medrxiv.org/content/early/2021/08/05/2021.08.04.21261561}, eprint = {https://www.medrxiv.org/content/early/2021/08/05/2021.08.04.21261561.full.pdf}, journal = {medRxiv} }